Outlook Therapeutics regains Nasdaq minimum bid price compliance, delisting risk removed

Outlook Therapeutics, Inc.

Received Nasdaq letter on June 26, 2026 confirming compliance with bid price rule 5550(a)(2).
Closing bid price was $1.00 or greater for ten consecutive business days from June 11-25, 2026.
Prior delisting notice from February 18, 2026 for failing minimum bid price is now closed.
Common stock (OTLK) remains listed on Nasdaq Capital Market without further action needed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.